

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

JUNE 17, 2008

-----  
ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioMarin Pharmaceutical Inc.  
File No. 0-26727 - CF#21611  
-----

BioMarin Pharmaceutical Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the below exhibits to a Form 10-K filed on February 28, 2008.

Based on representations by BioMarin Pharmaceutical Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.30	through February 27, 2018
Exhibit 10.31	through February 27, 2018
Exhibit 10.32	through February 27, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Michael Reedich  
Special Counsel